The altered expression of galectins has been implicated in bladder cancer malignancy [93], and both galectin-1, -2, -3, and -8 were suggested as potential disease markers and possible targets for bladder cancer therapy [94]. The gene discussed is LGALS1; the disease is urinary bladder carcinoma.